CMS unleashed a slew of proposals July 29, including 2020 payment rule proposals and a requirement for hospitals to publish the payer-specific negotiated prices of healthcare services.

AI and deep learning can extract molecular markets of breast cancer from tissue morphology and assist pathologists in a mass-scale molecular profiling, according to new research published in JAMA Network Open.

Deep reinforcement learning enabled by AI can help physicians figure out whether opioids would truly be better than other interventions for patients suffering pain in intensive care units.

Plastic surgeons can apply “emotional AI” algorithms to social media as a way of predicting which specific services will bring in business, according to a study running in the August edition of Plastic and Reconstructive Surgery.

Seemingly innocuous web browser extensions are actually a gateway for health and other data to be collected––and even put up for sale, according to Geoffrey Fowler, technology columnist for The Washington Post.

Pfizer, one of the nation’s largest pharmaceutical companies, is merging its off-patent and generic drug business with Mylan, a global generic and specialty pharmaceutical company based in the Netherlands. The spinoff deal is expected to close mid-2020, pending shareholder and regulatory approvals.

President Trump is reportedly working on another executive order targeting rising drug prices, according to Reuters. 

A handful of hospitals in the Texas panhandle are creating a telemedicine network that extends specialist care—including cardiology—to patients in more rural areas of the state.

The venture arm of 32-hospital UnityPoint Health is partnering with VIDA Diagnostics, investing $1 million to fine-tune and broaden the use of VIDA’s AI software for flagging signs of trouble in lung images.

The behavioral healthcare services space is gaining traction in the larger healthcare sector, supported by higher mergers and acquisition activity year to date.